{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"99.1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"106"}],"units":"Participants"}],"description":"An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and which does not necessarily have to have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal laboratory finding, for example), symptom, or disease temporally associated with the use of a pharmaceutical product, whether or not considered related to the pharmaceutical product. Preexisting conditions which worsen during a study are also considered as AEs. AEs were reported based on the NCI-CTCAE, v4.0. As pre-specified in the protocol data reported is combined for Arms G and H. Values have been rounded off to the nearest whole number.","groups":[{"description":"Participants with DLBCL received pola (lyophilized formulation), 1.8 mg/kg, as IV infusion on Day 2 of Cycle 1 (each cycle is 21 days), and thereafter on Day 1 of Cycles 2 to 6. Participants also received bendamustine 90 mg/m\\^2, as IV infusion on Days 2 and 3 of Cycle 1, and thereafter on Days 1 and 2 of Cycles 2 to 6 and rituximab, 375 mg/m\\^2, as IV infusion on Day 1 of Cycles 1 to 6, in combination with pola.","id":"OG000","title":"Arm G+H (Phase II NF Cohort): Pola+BR in DLBCL"}],"paramType":"NUMBER","populationDescription":"Safety population consisted of all ITT participants from Arms G+H (Phase II NF Cohort) who received at least one dose of study medication.","reportingStatus":"POSTED","timeFrame":"From Month 37 to Month 84 (up to approximately 47 months)","title":"Arm G+H (Phase II NF Cohort): Percentage of Participants With AEs","type":"PRIMARY","unitOfMeasure":"percentage of participants"}